Composition comprises (a) at least one first compound comprising celecoxib etoricoxib lumiracoxib parecoxib rofecoxib valdecoxib valicoxib and (b) at least one second compound comprising: e.g. indoprofen ibuproxam ketoprofen ketorolac loxoprofen naproxen naproxen sodium oxaprozin pirprofen suprofen tiaprofenic acid and alminoprofen; salicylamide and salicyl salicylate; aceclofenac acemetacin and alclofenac; mefenamic acid flufenamic acid and meclofenamic acid; ampyrone azapropazone and clofezone...

Disclosed is the use of a prostaglandin (PH) compound of formula (II) where the substituents are as disclosed in the description

Disclosed is a solid oral dosage pharmaceutical tablet comprising a first layer including at least one opioid, the first layer disposed between two adjacent controlled release layers, at least one of said adjacent controlled release layers including at least one non-opioid analgesic, wherein: a. the two adjacent controlled release layers cover substantially the entire first layer around a peripheral edge thereof, and/or b. a portion of the two adjacent controlled release layers are joined into a...

PURPOSE: A soluble drug delivery system is provided to prevent early drug release and to directly apply to a lesion. CONSTITUTION: A novel drug delivery system which enables sustained release contains 0.01-30 weight% of drug with positive charge and 0.01-30 weight% of multivalent cation. The drug with positive charge is selected from Teicoplanin dexamethasone disodium phosphate cefalotin sodium colistimethate sodium and Tolmetin sodium. The multivalent cation is selected from Mg^2+ Ca^2+ Sr^2+ B...

The present invention relates to co-crystals of duloxetine and co-crystal formers selected from COX-INHIBITORs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain. Specific COX-INHIBITORS are naproxen and tolmetin.

The present invention relates to co-crystals of duloxetine and co-crystal formers selected from COX-INHIBITORs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain. Specific COX-INHIBITORS are naproxen and tolmetin.

The present invention relates to co-crystals of duloxetine and co-crystal formers selected from COX-INHIBITORs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain. Specific COX-INHIBITORS are naproxen and tolmetin.

The present invention relates to novel process for the preparation of tolmetin sodium by employing easily available starting material and suitable reaction conditions. This invention is further related to novel crystalline forms of tolmetin methyl ester tolmetin and tolmetin sodium and their process for the preparation.